References
- 1. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2022. Available from: http://goldcopd.org. Last accessed: 11 March 2022.
- 2. Almagro P, Calbo E, Echaguien A et al. Mortality after hospitalization for COPD. Chest 2002; 121(5):1441-1448.
- 3. Connors A, Dawson N, Thomas C et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to understand prognoses and preferences for outcomes and risks of treatments) American Journal of Respiratory and Critical Care Medicine 1996; 154(4):959-967.
- 4. Gudmundsson G, Gislason T, Lindberg E et al. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respiratory Research 2006; 7(1):109.
- 5. Kim S, Clark S, Camargo C. Mortality after an emergency department visit for exacerbation of chronic obstructive pulmonary disease. COPD: Journal of COPD 2006; 3(2):75-81.
- 6. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121(5):1434-1440.
- 7. Piquet J, Chavaillon J-M, David P, Martin F, Blanchon F, Roche N, French College of General Hospital Respiratory Physicians (CPHG). High-risk patients following hospitalisation for an acute exacerbation of COPD. Europ Respir J 2013; 42:946-955.
- 8. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60(11):925-931.
- 9. Divo M, Cote C, Torres J et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2012;186(2):155-161.
- 10. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. The Am J Med 2006; 119(10):812-819.
- 11. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32:962-969.
- 12. Benson R, Kazmi N, Pocock A et al. Impact of diabetes in patients admitted with acute exacerbation of COPD [Abstract 883s]. Eur Respir J 2012; 40(Suppl. 56).
- 13. Schelini K, Tanni S, Zamuner A et al. The influence of metabolic syndrome in mortality rate of COPD patients: a five years follow up study [Abstract 81s]. Eur Respir J 2012; 40(Suppl 56).
- 14. Holmgaard DB, Mygind LH, Titlestad IL et al. Serum vitamin D in patients with chronic obstructive lung disease does not correlate with mortality – results from a 10-year prospective cohort study. PLoS ONE 2013; 8:e53670.
- 15. Borissova A-M, Shinkov A, Vlahov J et al. Determination of the optimal level of 25(OH)D in the Bulgarian population. Endocrinologia 2012; 17(3):135-142.
- 16. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diab Care 2012; 35:S64-S71.
- 17. Alberti KGMM, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640–1645.
- 18. Miller MR, Hankinson J, Brusasco V et al. Standardisation of spirometry. Eur Respir J 2005; 26:319–338.
- 19. Mekov E, Slavova Y, Tsakova et al. Vitamin D deficiency and insufficiency in hospitalized COPD patients. PLoS ONE 2015; 10(6):e0129080.
- 20. Mekov E, Slavova Y, Tsakova A et al. Metabolic syndrome in hospitalized patients with chronic obstructive pulmonary disease. PeerJ 2015; 3:e1068.
- 21. Mekov E, Slavova Y, Tsakova A et al. One-year mortality after severe COPD exacerbation in Bulgaria. PeerJ 2016; 4:e2788.